GlassScriptPhysician profile
Jay S Rosen
NPI 1477521706
$3,345.01
in general payments reported to CMS, 2019-2025
30 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $103 · 2021: $286 · 2022: $1,030 · 2023: $630 · 2024: $546 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.53 |
| Education | $185.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $769.83 | 2022 | |
| Astellas Pharma US INC | $515.84 | 2019-2024 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $235.53 | 2023-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $225.21 | 2022-2023 | |
| Procept Biorobotics Corporation | $186.22 | 2024 | Aquabeam System |
| Immunitybio, INC. | $153.85 | 2024 | |
| Glaxosmithkline, LLC. | $146.78 | 2019-2024 | Trelegy Ellipta |
| Antares Pharma, INC. | $127.02 | 2019-2025 | Xyosted |
| Comsort, INC | $100.00 | 2019 | |
| Tolmar, INC. | $87.03 | 2024-2025 | Jatenzo, Eligard |
| Pfizer INC. | $81.75 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $76.25 | 2023-2025 | Pylarify |
| Myovant Sciences INC. | $64.08 | 2021-2022 | |
| Teleflex LLC | $62.94 | 2021-2025 | Barrigel |
| Ferring Pharmaceuticals INC. | $60.52 | 2019-2025 | Adstiladrin |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $52.26 | 2019-2020 | |
| Olympus America INC. | $47.30 | 2021-2024 | Itind System |
| Amgen INC. | $43.72 | 2022-2023 | Evenity, Prolia |
| Dendreon Pharmaceuticals LLC | $39.06 | 2019-2023 | Provenge |
| Endo USA, INC. | $38.03 | 2025 | Xiaflex, Aveed |
| Novo Nordisk INC | $31.44 | 2023 | Rybelsus, Ozempic |
| Axonics, INC. | $30.79 | 2023 | Axonics, Bulkamid |
| Lilly USA, LLC | $30.40 | 2023-2024 | Mounjaro, Zepbound |
| Kerecis Limited | $28.19 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Endo Pharmaceuticals INC. | $25.97 | 2019 | |
| Abbott Laboratories | $23.49 | 2021 | |
| 180 Medical, INC. | $19.38 | 2025 | |
| Accord Healthcare, INC. | $16.44 | 2023 | |
| Aytu Biopharma, INC. | $13.23 | 2019 | |
| Allergan, INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.